Recently, Asymmetrex LLC joined forces with a new public-private Manufacturing USA Initiative, the Advanced Regenerative Manufacturing Institute (ARMI). ARMI highlighted Asymmetrex in its New Member Spotlight. This member spotlight goes into detail about the crucial hurdle regenerative medicine is currently facing — a quantitative discipline for tissue stem cells. Dr. James Sherley speaks to ARMI
The Advanced Regenerative Manufacturing Institute (ARMI) will receive more than $300 million in public-private investment from leading manufacturers, universities, nonprofit organizations and the federal government to develop scalable manufacturing processes for engineered tissues and organs. Asymmetrex LLC is part of a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI). Headquartered in Manchester,
Asymmetrex Founder and Director James L. Sherly, M.D., Ph.D. recently wrote an article for The Scientist magazine that addresses the ethics around the peer-review of academic manuscripts submitted for publication in research journals. “Whether co-reviewers are named or not, this practice, along with the more patently unethical ghostwriting, has no defensible place in the live
Director James Sherley M.D., Ph.D. visits COAACH at North Carolina A&T State University to talk with future biotech entrepreneurs about the principles of biotechnology commercialization illustrated with the origin story of Asymmetrex. Listen to the talk here.
Massachusetts stem cell biotechnology company Asymmetrex began sponsorship of a new informational podcast in October of this year. Titled “Counting Stem Cells For A New Era Of Medicine,” the educational podcast explains and amplifies the FDA’s recent attention to a long-standing, significant deficiency in stem cell medical practice, giving patients stem cell treatments without knowing
On October 2, 2019, the United Kingdom Intellectual Property Office issued a patent to Massachusetts stem cell biotechnology company Asymmetrex. The patent covers the company’s invention of the first and only technology for counting tissue stem cells specifically and identifying agents that affect tissue stem cells, positively or negatively. The new patent is another advance
As the field of stem cell medicine begins to wake up to its critical need for tissue stem cell-specific dosing, biotechnology tools company Asymmetrex is leading the way. This week in Boston, at the 2019 Outsourcing in Clinical Trials New England conference, the company’s director gave a pointed presentation on how the current lack of
Dr. James L. Sherley speaks at the 5th Annual Perinatal Stem Cell Society Congress in Salt Lake City, Utah, on February 28-March 1, 2019. His talk was about the continued development of a first technology for specific and accurate counting of perinatal and postnatal tissue stem cells. Watch the video below to learn more.
On May 16, at the ASTM International May Committee Meeting in Denver, Colorado, Massachusetts stem cell biotechnology company Asymmetrex received unanimous approval of its proposal for an interlaboratory evaluation of the company’s AlphaSTEM Test™ technology for counting therapeutic adult tissue stem cells. Highlighting the importance of the approval, a day earlier, the Standards Coordinating Body
Today, May 16, at the ASTM International May Committee Meeting in Denver, Colorado, Massachusetts stem cell biotechnology company Asymmetrex will present a proposal for an interlaboratory evaluation of the company’s AlphaSTEM Test™. Approval of this ASTM evaluation will be an important step in Asymmetrex’s plan to establish the AlphaSTEM Test™ as a stem cell industry